AXGN
NASDAQAxogen Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$39.84+0.67 (+1.71%)
01:30 PM07:45 PM
News · 26 weeks53+100%
2026-01-182026-07-12
Mix3190d
- Insider21(68%)
- SEC Filings4(13%)
- Other3(10%)
- Leadership1(3%)
- Offering1(3%)
- Earnings1(3%)
Latest news
25 items- PRAxogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are availabl
- INSIDERSEC Form 4 filed by Director Burke William P. Mr.4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Tyndall Joseph A.4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Levine Alan M4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson John4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Paul4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Wendell Amy Mcbride4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Director Weiler Kathy Johnson4 - Axogen, Inc. (0000805928) (Issuer)
- SECAxogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- INSIDERDirector Levine Alan M converted options into 14,150 shares, increasing direct ownership by 39% to 50,893 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Weiler Kathy Johnson converted options into 14,150 shares (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Wendell Amy Mcbride converted options into 14,150 shares, increasing direct ownership by 15% to 107,976 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Thomas Paul converted options into 18,867 shares, increasing direct ownership by 139% to 32,395 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Tyndall Joseph A. converted options into 14,150 shares (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Johnson John converted options into 14,150 shares (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Burke William P. Mr. converted options into 14,150 shares, increasing direct ownership by 14,150% to 14,250 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- PRThe Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in medicine. The premise is no longer to put something foreign into the body when tissue is lost. The premise is to give the body the scaffolding, the cues, and the conditions it needs to grow back what was taken — and then have that scaffolding dissolve, leaving only the patient's own living tissue behind.On May 21, 2026, a new Nasdaq ticker put a public-mark
- INSIDERDirector Wendell Amy Mcbride exercised 1,647 shares at a strike of $14.85 and sold $70,162 worth of shares (1,647 units at $42.60) (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Johnson John sold $477,968 worth of shares (11,050 units at $43.26) and exercised 11,050 shares at a strike of $7.04 (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Weiler Kathy Johnson exercised 16,344 shares at a strike of $6.95 and sold $720,623 worth of shares (16,344 units at $44.09) (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERChief Marketing Officer Kemp Jens sold $173,761 worth of shares (4,000 units at $43.44), decreasing direct ownership by 5% to 72,451 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERCFO Hartley Lindsey Marie sold $45,897 worth of shares (1,051 units at $43.67) and exercised 5,463 shares at a strike of $8.24, increasing direct ownership by 7% to 65,146 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSales VP Quackenbush Doris sold $168,720 worth of shares (3,878 units at $43.51), decreasing direct ownership by 4% to 92,416 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERNew insider Quackenbush Doris claimed ownership of 96,294 shares (SEC Form 3)3 - Axogen, Inc. (0000805928) (Issuer)
- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
AXGN FAQ
6 questionsWhat does Axogen Inc. do?
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged...Where does AXGN stock trade?
Axogen Inc. (AXGN) is listed on NASDAQ.What sector and industry is AXGN in?
Axogen Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about AXGN?
Axogen Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $4000.00 price target on 2026-02-19. Recent price targets range from $1300.00 to $4000.00.What companies are similar to AXGN?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare AXGN side-by-side with any of them on Quantisnow.How can I track AXGN on Quantisnow?
Quantisnow aggregates Axogen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXGN to receive live email and push alerts on every new disclosure.